Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

Matt Kalaycio named chair of board of directors at NCCN

Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding Kalaycio in the position he has held since 2022.

April 12, 2024

Vol.50 No.15

In Brief

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Christopher Hourigan, a senior investigator and chief of the Laboratory of Myeloid Malignancies at the National Institutes of Health, will join Virginia Tech as a professor with the institute and director of its Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Clinical Roundup

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.

March 29, 2024

Vol.50 No.13

In Brief

Jasper Health, LLS collaborate to support blood cancer patients

Jasper Health, a virtual cancer care navigation and supportive care solution, is collaborating with The Leukemia & Lymphoma Society to provide comprehensive support and resources to blood cancer patients and their caregivers.

March 15, 2024

Vol.50 No.11

Drugs & Targets

FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma

FDA granted accelerated approval to Brukinsa (zanubrutinib) with obinutuzumab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 08, 2024

Vol.50 No.10

Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

YOU MAY BE INTERESTED IN

Matt Kalaycio named chair of board of directors at NCCN

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

Jasper Health, LLS collaborate to support blood cancer patients

FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma

Renew today!

Subscriber content

Login